Microbiome company BiomX Ltd said on Monday that it has entered into an agreement to license a new set of bacterial targets for the development and commercialisation of phage therapies for the treatment of orphan liver disease Primary Sclerosing Cholangitis (PSC) from JSR Corporation, Japan.
PSC is reportedly a rare progressive disease of the liver, characterised by inflammation and damage to hepatic bile ducts, leading to fibrosis and ultimately liver failure, cirrhosis and an increased risk of cancer.
Utilising its advanced discovery and development capabilities in phage therapy, the company discovered phage that eradicate the pathogenic strains and is developing a customised phage cocktail as a therapeutic for PSC.
According to the company, Dr Takanori Kanai, professor of Department of Internal Medicine Division of Gastroenterology and Hepatology at Keio University School of Medicine and his research team, discovered the PSC specific strains of Klebsiella pneumoniae (Kp) that disrupt the epithelial barrier in the microbiome of patients.
The company added the presence of those strains triggers additional bacterial translocation and liver inflammatory responses. The results of this study were recently published in Nature Microbiology.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Halia Therapeutics collaborates with Canary Speech
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007
Sanofi reports FDA approval for Dupixent in paediatric EoE treatment